Abstract
In the field of oncology therapeutics, biomarker assays play an increasingly important role from discovery research to patient management. Companion Diagnostic (CDx) assays play an important role in precision medicine, having a specific clinical utility to aid in the identification of patients eligible to receive a therapeutic treatment, or to predict which patients may respnd to a targeted therapy. CDx assays may also affect the design of clinical trials, which can lead to higher patient response rates when the right patients are selected for treatment. CDx assays can also accelerate the introduction of new therapeutics, enabling a smaller number of patients to be enrolled in studies, reducing the number of patients exposed to investigational or approved therapeutics, thereby decreasing the chance of side effects. With the introduction of immuno-oncology drugs such as anti-PD-L1 and anti-PD-1 therapeutics, biomarker assays have become even more critically important in understanding the interactions between the tumor cells and immune response, and predicting patient responses. This chapter will review the history of CDx and present a high-level overview of the development path of CDx. It will also provide a survey of current FDA-approved or FDA-cleared CDx assays, examine some of the challenges in CDx development, and explore technologies and assay types applicable to CDx important in the next generation of oncology therapeutics.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Guidance for Industry and Food and Drug Administration Staff - In Vitro Companion Diagnostic Devices. July 14, 2011. https://www.document-center.com/standards/show/FDA-IN-VITRO-COMPAN/history/2011%20DRAFT.
- 2.
In Vitro Companion Diagnostic Devices. Guidance for Industry and Food and Drug Administration Staff. August 6, 2014. https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM262327.pdf.
- 3.
Principles for Co-development of an In Vitro Companion Diagnostic Device with a Therapeutic Product: Draft Guidance for Industry and Food and Drug Administration Staff Document issued on July 15, 2016: https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM510824.pdf.
References
Romond EH, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.
Ménard, et al. HER2 as a prognostic factor in breast cancer. Oncology. 2001;61(Suppl 2):67–72.
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001;61(Suppl 2):37–42.
Baselga J. Clinical trials of Herceptin(trastuzumab). Eur J Cancer. 2001;37(Suppl 1):S18–2.
Lee JW, Devanarayan V, Barrett YC, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res. 2006;23(2):312–28.
Olsen D, Jorgensen JT. Companion diagnostics for targeted cancer drugs – clinical and regulatory aspects. Front Oncol. 2014;4:105.
Audette J. FDA introduces a new test concept: “complementary diagnostics”. Amplion; 2015.
Novotny JF Jr, Cogswell J, Inzunza H, et al. Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy. Ann Oncol. 2016;27(10):1966–9.
Meijuan L. Statistical methods for clinical validation of follow-on companion diagnostic devices via an external concordance study. Stat Biopharma Res. 2016;8(3):355–63.
Hirsch FR, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2016;12(2):208–22.
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research. In vitro companion diagnostic devices: guidance for industry and food and drug administration staff. 2014.
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Principles for codevelopment of an in vitro companion diagnostic device with a therapeutic product: draft guidance for industry and food and drug administration staff. 2016.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Welcher, R. (2019). Use of Companion Diagnostics (CDx) and Predictive Biomarkers for Cancer Targeted Therapy: Clinical Applications in Precision Medicine. In: Badve, S., Kumar, G. (eds) Predictive Biomarkers in Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-95228-4_49
Download citation
DOI: https://doi.org/10.1007/978-3-319-95228-4_49
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95227-7
Online ISBN: 978-3-319-95228-4
eBook Packages: MedicineMedicine (R0)